XFOR — X4 Pharmaceuticals Income Statement
0.000.00%
- $97.40m
- $71.36m
Annual income statement for X4 Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 3 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 52.3 | 63 | 85.1 | 87.6 | 108 |
Operating Profit | -52.3 | -60 | -85.1 | -87.6 | -108 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -52.8 | -62 | -88.7 | -93.8 | -101 |
Provision for Income Taxes | |||||
Net Income After Taxes | -52.8 | -62.1 | -88.7 | -93.9 | -101 |
Net Income Before Extraordinary Items | |||||
Net Income | -52.8 | -62.1 | -88.7 | -93.9 | -101 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -53.4 | -62.1 | -103 | -96.4 | -101 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.16 | -3.09 | -3.74 | -1.52 | -0.569 |